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Summary Postmenopausal patients with primary breast cancer were treated with tamoxifen, ethynyl-
oestradiol or prednisolone for up to 12 days before mastectomy and the effects of pretreatments with these
drugs on the activities of phosphofructokinase (PFK), 6-phosphogluconate dehydrogenase (6PGDH) and a-
glycerolphosphate dehydrogenase (a-GPDH) in the carcinomas were compared with age, stage and
menopausal status matched untreated controls. The administration of tamoxifen or prednisolone resulted in a
significant increase in the activity of a-GPDWH and the a-GPDH/6PGDH ratio, whereas ethynyl-oestradiol
treatment produced a significant decrease in the activity of the enzyme and the ratio. When tamoxifen and
ethynyl-oestradiol were administered together, it was found that tamoxifen failed to reverse the oestrogen-
induced reduction in the activity of a-GPDH. Since increased activity of the enzyme or a higher a-
GPDH/6PGDH ratio are associated with a lower risk of recurrence (Deshpande et al., 1981), it is postulated
that the beneficial effects of tamoxifen or prednisolone in terms of prolongation of the relapse free interval
might be mediated via alterations in the activity of a-GPDH in micrometastases. The activities of PFK and
6PGDH remained unaffected by these treatments.
For the past eight years we have been exploring the
usefulness of the measurements of the activities of
certain enzymes of carbohydrate metabolism in
primary carcinomas in prognosis in human breast
cancer and have reported that higher activities of
phosphofructokinase (PFK) and 6-phosphogluco-
nate dehydrogenase (6-PGDH) or lower activity of
a-glycerolphosphate dehydrogenase (cx-GPDH) or
lower oa-GPDH/6PGDH ratios are associated with
a high risk of recurrence (Deshpande et al., 1981).
Of the three enzymes, PFK is a key regulatory
enzyme and the first enzyme unique to glycolysis.
The other two enzymes are neither directly
opposing nor key regulatory enzymes. They are
involved in the channelling of substrates into the
pathways of fat deposition (oe-GPDH) or nucleic
acid synthesis and production of reduced pyridine
nucleotides (6PGDH). Yet their utility in predicting
the likelihood of recurrence has been proven and
therefore we are currently investigating whether the
activities of these enzymes are amenable to
manipulation. As a first step in this project we have
examined the direct effects of tamoxifen, ethynyl-
oestradiol (EE), prednisolone and various cytotoxic
drugs, on the activities of these enzymes in MCF-7
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cells in monolayer culture and observed that
treatment of these cells with tamoxifen increases
both the activity of ax-GPDH and a-GPDH/6PGDH
ratios whereas EE and prednisolone were without
any effect. Of the cytotoxic drugs investigated so
far, only adriamycin, at low doses, was found to con-
sistently produce an increase in the activity of a-
GPDH and x-GPDH/6PGDH ratios (Mitchell &
Deshpande, 1984). In view of these findings we
decided to investigate whether treatment of patients
with these drugs before mastectomy would induce
similar changes in the activities of these enzymes in
the carcinomas. In this paper we report on the
effects of pretreatment with tamoxifen, EE or
prednisolone on the activities of these enzymes in
primary carcinomas from a series of age- and stage-
matched postmenopausal patients.
Materials and methods
Clinical
The patients in this series of investigations were
all postmenopausal women (age range 57-76) with
carcinoma of the breast awaiting mastectomy. The
presence ofcarcinoma was confirmed by histological
examination of the tumour. For personal reasons
some of them were unable to come to the hospital
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for immediate treatment and therefore we took the
opportunity to treat them with various drugs. The
informed consent of each patient was obtained
before the start of treatment prior to mastectomy.
The patients were treated for between 7 and 12 days
before mastectomy. The dosage of drugs was as
follows: tamoxifen 2x20mgday-1, EE 2mgday-1,
prednisolone 3 x 2.5 mgday1- . The controls were 20
age, stage- and menopausal status-matched un-
treated patients. At mastectomy, a piece of carci-
noma weighing 400mg was removed, wrapped in
aluminium foil and frozen on solid CO2. It was then
transferred to the laboratory where it remained in
liquid nitrogen until further processing.
Biochemical
The tumours were partially thawed, cut into small
pieces after removal of the surrounding fat,
weighed and homogenized in a Silverson
homogenizer in the medium described by Shonk &
Boxer (1964). A small aliquot of each homogenate
was kept for the estimation of DNA and the
remainder of the homogenate was centrifuged in a
refrigerated centrifuge (4°C, 800g) for 20min. The
supernatant was decanted off, adjusted to a
concentration of 50mgml-P and used as the source
of enzymes. The activities of PFK, 6PGDH and a-
GPDH were estimated according to the method of
Shonk & Boxer (1964). The method of Burton
(1956) was used for the estimation of DNA. The
activities are expressed as Umg-' DNA where a
unit is defined as that amount of enzyme which will
catalyze the conversion of 1 umol substrate min-'.
The results are expressed as mean+s.d. for each
group. The means were tested for statistical
significance by Student's t-test.
Results
The effects of the treatment of patients with
tamoxifen, EE and both on the activities of PFK,
6PGDH, a-GPDH and a-GPDH/6PGDH ratios
are presented in Table I. Tamoxifen treatment
resulted in a significant increase in the activity of a-
GPDH and x-GPDH/6PGDH ratios whereas EE
treatment reduced the activity of the enzyme and
the ratio. When patients were treated with a
combined dose of the two drugs, the results show
that EE was able to reverse the tamoxifen-induced
increase in the activity of a-GPDH.
The effects of treatment with prednisolone are
shown in Table II. The glucocorticoid treatment
resulted in a significant increase in the activity of a-
GPDH and a-GPDH/6PGDH ratios.
Discussion
Since there are significant quantitative differences in
the activities of certain enzymes in carcinomas
between patients who are at a higher risk of
recurrence and others in whom the risk is low,
theoretically it should be possible to alter the
enzyme patterns in the high risk group and
investigate whether this results in the prolongation
of the disease-free interval. In practice, it would
mean inducing quantitative reductions in the
Table I Effects of ethynyl-oestradiol (2mgday'- for up to 12 days) and
tamoxifen (40mgday-1 for up to 12 days) treatments before mastectomy on the
activities of PFK, 6PGDH, a-GPDH and a-GPDH/6PGDH ratios in human
breast carcinomas. The results are expressed as units of enzyme activitymg1
DNA and are presented as mean+s.d.
Ethynyl-
Ethynyl- oestradiol+
Controls Tamoxifen oestradiol tanoxifen
(n=20) (n=9) (n=JO) (n=7)
PFK 0.074+0.043 0.075+0.036 0.134+0.082 0.072+0.024
6PGDH 0.073+0.045 0.050+0.031 0.074+0.021 0.054+0.014
a-GPDH 0.078+0.027 0.147+0.083a 0.045+0.017b 0.044+0.020c
a-GPDH 0.95+0.56 3.92+2.69a 0.48+0.026b 2.09+2.04
6PGDH
aSignificant differences between controls and tamoxifen treated patients P<0.01.
bSignificant differences between controls and ethynyl-oestradiol treated patients
P<0.01.
cSignificant differences between tamoxifen and tamoxifen+ethynyl-oestradiol
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Table II Effects of prednisolone (2.5mg three
times day-1 for up to 12 days) treatment before
mastectomy on the activities of PFK, 6PGDH,
a-GPDH and a-GPDH/6PGDH ratios in
human breast carcinomas. The results are
expressed as units of enzyme activitymg1
DNA and are presented as mean+s.d.
Controls Prednisolone
(n =20) (n =lo)
PFK 0.074+0.043 0.100+0.042
6PGDH 0.073+0.045 0.070+0.031
a-GPDH 0.078+0.027 0.144+0.079a
a-GPDH 0.95+0.56 1.58+0.74a
6PGDH
aSignificant differences between controls and
prednisolone treated patients (0.01 <P<0.001).
activities of PFK and 6PGDH and/or an increase
in the activity of a-GPDH. As most drugs currently
used in adjuvant therapies produce minor beneficial
effects in terms of prolonged disease-free interval
(Fisher et al., 1975; Bonadonna et al., 1976; Meakin
et al., 1979; Baum et al., 1983; Goldhirsch et al.,
1984; Howell et al., 1984), it was felt that our
hypothesis might be more acceptable if it could be
shown that at least some of these drugs act on
carcinomas in such a way as to induce changes in
activities of these enzymes. Therefore we have
attempted to investigate the effects of two drugs, viz.
tamoxifen and prednisolone, which are used in the
endocrine treatments of these patients.
Tamoxifen is the most widely used drug in the
treatment of endocrine responsive cancer. It was
originally felt that its action on the carcinoma was
mediated via the occupation of oestradiol binding
sites in the tissue but recent studies indicate that it
also antagonizes calmodulin (Lam, 1984), inhibits
prostaglandin synthetase (Richie, 1978), suppresses
plasminogen activator activity (Katzenellenbogen
et al., 1984), arrests the growth of cancer cells in
the Go/GI phase and induces a decline in the
percentage of S-phase cells (Sutherland et al., 1983).
The last finding indicates to us that the clinical
observations of a prolonged disease-free interval in
patients who received tamoxifen as an adjuvant to
mastectomy might be due to such alterations to the
growth rate of the carcinoma and that the finding
of changes in cell cycle kinetics might be related to
a reduction in the generation of energy for cell
division. Since a-GPDH is the enzyme involved in
the channelling of substrates into the pathways of
fat deposition thereby depleting the amounts
available for energy generation an increase in its
activity both, in MCF-7 human breast cancer cells
in monolayer culture (Mitchell & Deshpande, 1984)
and in primary carcinomas from patients, after
treatment with tamoxifen suggests that this might
be associated with the retention of the malignant
cells in the GO/GI phase of the cell cycle which in
turn produces inhibition of cell growth, leading to
prolongation of the disease-free interval.
It is generally believed that a continuous
oestrogenic stimulus is required to maintain the
growth of breast carcinomas and that drugs which
inhibit the action(s) of oestrogens will induce
regressions in these tumours. In order to examine
whether there is such an antagonism between
oestrogens and tamoxifen in the activities of these
enzymes, we have treated patients with tamoxifen,
EE and tamoxifen plus EE. The data presented in
Table I show that treatment with tamoxifen
resulted in a significant increase and that with EE a
significant decrease in the activity of a-GPDH and
the a-GPDH/6PGDH ratio. This latter finding adds
support to the hypothesis that a lower activity of
the enzyme might be associated with a higher
growth rate of the carcinoma. However, the data
from patients treated with a combined dose of
tamoxifen and EE suggest that EE is quite capable
of reversing the tamoxifen-induced rise in the
activity of the enzyme indicating that it is the
oestrogen which determines the overall activity of
the enzyme.
Prednisolone has been used as a treatment
modality in both, endocrine and cytotoxic drug
therapies (Meaking et al., 1979, Goldhirsch et al.,
1984). Since the drug is rarely administered alone, it
is difflcult to judge whether it can act alone or only
in association with other treatments such as ovarian
irradiation or cytotoxic drugs. The data reported in
Table II indicate that like tamoxifen, it is capable of
increasing the activity of a-GPDH and a-
GPDH/6PGDH ratios. Since these two drugs have
different biological activities, the similarity in their
action on the activity of a-GPDH suggests that
either they act by binding to specific individual
receptors or there might be a common focus
involved in the regulation of the activity of the
enzyme in breast carcinomas. It would be
interesting to investigate other factors which
increase the activity of the enzyme and to assess
their usefulness clinically in patients who are failing
to respond to tamoxifen or prednisolone.
In conclusion, these investigations indicate that
both tamoxifen and prednisolone which are used in
adjuvant endocrine therapies might be acting on the
carcinoma in such a way as to induce alteration in
the activity of a-GPDH which might be associated
with changes in the growth of the carcinoma. We
are currently extending these studies to investigate
the role of certain cytotoxic drugs on the activities
of the enzymes.
The authors are indebted to Drs R.D. Bulbrook and R.D.
Rubens for their help in the preparation of the
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